Phase II Evaluates Vemurafenib/Obinutuzumab in Hairy Cell Leukemia

December 6, 2019
Justin Taylor, MD

Justin Taylor, MD, discusses the rationale for an ongoing phase II trial that is exploring the combination of vemurafenib, a BRAF inhibitor, plus the anti-CD20 monoclonal antibody obinutuzumab in previously untreated patients with classical hairy cell leukemia.

Justin Taylor, MD, attending physician at Memorial Sloan Kettering Cancer Center (MSKCC), discusses the rationale for an ongoing phase II trial (NCT03410875) that is exploring the combination of vemurafenib (Zelboraf), a BRAF inhibitor, plus the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) in previously untreated patients with classical hairy cell leukemia.

This is the first trial to look at targeted therapies in the frontline for treatment of patients with hairy cell leukemia, Taylor says. At MSKCC and the University of Perugia in Italy, vemurafenib was evaluated in a phase II study in the relapsed setting for this patient population. The data from that trial suggested good response rates with the targeted agent, Taylor explains, which led to the rationale for this ongoing trial.